PMID- 24878813
OWN - NLM
STAT- MEDLINE
DCOM- 20150702
LR  - 20140602
IS  - 1875-8592 (Electronic)
IS  - 1574-0153 (Linking)
VI  - 14
IP  - 2-3
DP  - 2014
TI  - An alternative and sensitive method based on LCM and Q-PCR for HER2 testing in 
      breast cancer.
PG  - 129-35
LID - 10.3233/CBM-130311 [doi]
AB  - Nowadays, HER2 testing in breast cancer represents a necessity for both 
      prognostic and therapy. Despite widespread use of immunohistochemistry (IHC) for 
      assessing HER2 status, there are some limitations to identify truly negative or 
      positive HER2 cases. Fluorescence in situ hybridization (FISH) or chromogenic in 
      situ hybridization (CISH) could solve the equivocal HER2 IHC cases but there is 
      no consensus on which is the best method. Consequently, finding a sensitive 
      method for HER2 testing is critical for the management of the disease. In 
      addition, tumor heterogeneity is an important factor which could affect accuracy 
      of molecular diagnostics. Laser capture micro-dissection (LCM) is used to isolate 
      pure cell populations from heterogeneous tumor tissue. The combination between 
      LCM and quantitative polymerase chain reaction (Q-PCR), the gold standard in 
      molecular biology for quantifying gene amplification levels, could define an 
      important tool to improve the molecular diagnostics of HER2 status.In our pilot 
      study we used LCM and Q-PCR to evaluate HER2 gene amplification for invasive 
      breast carcinoma samples. The samples were selected based on HER2 status assessed 
      by IHC and CISH. Our results demonstrated high sensitivity of Q-PCR for assessing 
      HER2 DNA amplification as well as a good concordance between Q-PCR and IHC/ CISH 
      assay.
FAU - Fetica, Bogdan
AU  - Fetica B
AD  - Department of Pathology, The Oncology Institute "Prof. Dr. Ion Chiricuta" 
      Cluj-Napoca, Romania The Research Center for Functional Genomics, Biomedicine and 
      Translational Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 
      Cluj-Napoca, Romania.
FAU - Balacescu, Ovidiu
AU  - Balacescu O
AD  - Department of Functional Genomics and Experimental Pathology, The Oncology 
      Institute "Prof. Dr. Ion Chiricuta", Cluj-Napoca, Romania The Research Center for 
      Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Hatieganu" 
      University of Medicine and Pharmacy, Cluj-Napoca, Romania.
FAU - Balacescu, Loredana
AU  - Balacescu L
AD  - Department of Functional Genomics and Experimental Pathology, The Oncology 
      Institute "Prof. Dr. Ion Chiricuta", Cluj-Napoca, Romania The Research Center for 
      Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Hatieganu" 
      University of Medicine and Pharmacy, Cluj-Napoca, Romania.
FAU - Rus, Meda
AU  - Rus M
AD  - Department of Functional Genomics and Experimental Pathology, The Oncology 
      Institute "Prof. Dr. Ion Chiricuta", Cluj-Napoca, Romania The Research Center for 
      Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Hatieganu" 
      University of Medicine and Pharmacy, Cluj-Napoca, Romania.
FAU - Berindan-Neagoe, Ioana
AU  - Berindan-Neagoe I
AD  - Department of Functional Genomics and Experimental Pathology, The Oncology 
      Institute "Prof. Dr. Ion Chiricuta", Cluj-Napoca, Romania Department of 
      Immunology, University of Medicine and Pharmacy, "Iuliu Hatieganu", Cluj-Napoca, 
      Romania The Research Center for Functional Genomics, Biomedicine and 
      Translational Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 
      Cluj-Napoca, Romania.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Cancer Biomark
JT  - Cancer biomarkers : section A of Disease markers
JID - 101256509
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Breast Neoplasms/genetics/*metabolism/pathology
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization/methods
MH  - Laser Capture Microdissection/*methods
MH  - Pilot Projects
MH  - Polymerase Chain Reaction/*methods
MH  - Real-Time Polymerase Chain Reaction
MH  - Receptor, ErbB-2/*analysis/genetics
MH  - Sensitivity and Specificity
OTO - NOTNLM
OT  - HER2
OT  - LCM
OT  - Q-PCR
OT  - breast cancer
EDAT- 2014/06/01 06:00
MHDA- 2015/07/03 06:00
CRDT- 2014/06/01 06:00
PHST- 2014/06/01 06:00 [entrez]
PHST- 2014/06/01 06:00 [pubmed]
PHST- 2015/07/03 06:00 [medline]
AID - 780450X27653X235 [pii]
AID - 10.3233/CBM-130311 [doi]
PST - ppublish
SO  - Cancer Biomark. 2014;14(2-3):129-35. doi: 10.3233/CBM-130311.